Previous studies focusing on the HRQoL of patients with HAE were mainly conducted in patients of European descent living in North America or Western Europe who have access to LTP treatments, approximately 40%–60% of these patients receiving C1‐INH and approximately 30% receiving attenuated androgens.37, 38. Here, SERPING1 is linked to hereditary angioedema.